Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Mechanism of action of evorpacept

Jong Chul Park • 13 Nov 2021
SITC 2021
General Evorpacept

Jong Chul Park, MD, Harvard Medical School, Boston, MA, discusses the mechanism of action of evorpacept; a fusion protein designed to inhibit the CD47-SIRPα pathway on myeloid cells. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Jong Chul Park

ASPEN-03: evorpacept in combination with pembrolizumab in patients with advanced HNSCC
2:03
ASPEN-03: evorpacept in combination with pembrolizumab in patients with advanced HNSCC
Jong Chul Park • 13 Nov 2021
Early results from ONCR-177-101: ONCR-177 alone or in combination with anti-PD-1 blockade
3:37
Early results from ONCR-177-101: ONCR-177 alone or in combination with anti-PD-1 blockade
Jong Chul Park • 13 Nov 2021

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals